Medicare AdvantageCoverageHigh impact
Brain Stimulation Treatments - Medicare Advantage (Revised)
Humana·Neurology, Neurosurgery, Pain Management·Medicare Advantage
Effective date
Nov 3, 2025
We identified it
Sep 9, 2026
Summary
This is a revised Medicare Advantage policy for brain stimulation treatments (effective 11/03/2025) that covers multiple neurological conditions including refractory epilepsy, Parkinson's disease, essential tremor, and dystonia. The policy consolidates coverage guidance for cortical stimulation, deep brain stimulation (DBS), directional DBS, thalamic stimulation, and magnetic resonance guided focused ultrasound (MRgFUS). Billing teams must ensure prior authorization aligns with specific MAC jurisdictions and applicable Local Coverage Determinations based on patient geography.
Action Required
By November 3, 2025: Billing and authorization teams must (1) Map patient locations to applicable Medicare Administrative Contractor (MAC) jurisdictions per the policy's geographic table (e.g., J6 for IL/MN/WI, JE for CA/HI/NV, JH for AR/CO/LA/MS/NM/OK/TX, JL for DE/DC/MD/NJ/PA); (2) Verify which specific Local Coverage Determination (LCD) applies to each brain stimulation treatment request based on patient state and MAC jurisdiction; (3) Update prior authorization workflows to reference the appropriate LCD/LCA numbers (L37421, L37790, L37729, L38495, L37761, L38506) and related CMS NCDs (160.24, 160.7, 160.2); (4) Configure billing system to capture required clinical documentation for coverage determination (diagnosis, failed medication trials for refractory conditions, seizure focus documentation for epilepsy cases); (5) Train staff on differences between covered modalities (cortical stimulation, DBS, directional DBS, thalamic stimulation, MRgFUS) and their specific clinical indications. Providers must document medical necessity per MAC requirements or claims will be denied. Update encounter templates to prompt for refractory/medication-resistant disease status.